SK hynix: Sold Out Through 2029 But CapEx Is The Focus

SK hynix maintains a Buy rating, supported by robust earnings, record operating margins and DRAM and HBM volumes effectively sold out through 2029. Long-term agreements cover more than half of 2027–2028 capacity; the company also has KRW 98.7T in net cash and substantial shareholder-return plans. Rising CapEx remains a market concern.

Analysis

The key underwriting question is not whether capacity is allocated, but whether the agreements lock in attractive pricing and returns after the required capacity additions. “Sold out” can describe volume without guaranteeing price, customer take-or-pay commitments, or protection from a downturn; verify contract terms, HBM mix, and realized pricing before capitalizing the claim into a longer-duration multiple. If demand commitments are firm while supply remains constrained, SK hynix could sustain pricing and cash generation. Conversely, aggressive capacity investment across the industry may turn today’s scarcity into excess supply, while customer concentration and rapid changes in accelerator architectures create demand and substitution risk. Net cash limits financing risk, but does not insulate equity value from a memory-cycle reversal.

Near term (days), an optimistic rating may support sentiment, but the trade is vulnerable to any market-wide de-rating of AI infrastructure. Over 1–3 months, track earnings revisions, HBM shipment/yield commentary, contract pricing, and capex guidance. Over 6–18 months, the decisive test is whether incremental HBM investment earns adequate returns without depressing conventional DRAM economics. The bullish thesis weakens if pricing or margins roll over despite allocated capacity, customers defer deliveries, or capex rises faster than cash generation.

Key Decisions for Investors

• Consider a staged long in SKHY on weakness rather than chasing the positive rating; the thesis is earnings durability, not an assumed valuation discount. Keep sizing conditional on current valuation and confirmation that contracted capacity carries meaningful pricing and delivery protection.
• Before adding, verify the scope and enforceability of the reported long-term agreements: HBM versus conventional DRAM, pricing mechanisms, cancellation or deferral rights, and customer concentration. Treat capacity allocation alone as an alert, not proof of guaranteed revenue or margins.
• For the next 1–3 months, monitor HBM yields and shipments, realized pricing, capex guidance, and revisions to forward earnings. A downgrade in these indicators despite strong allocation would challenge the market’s scarcity narrative.
• Falsification: reduce or exit the thesis if SK hynix reports weakening memory pricing or operating margins while capacity commitments remain high, or if capex expansion materially outpaces cash generation. The balance-sheet cushion lowers financing risk; it does not prevent cyclical multiple compression.